Cargando…
Novel non-AR therapeutic targets in castrate resistant prostate cancer
Castrate resistant prostate cancer (CRPC) remains a disease with significant morbidity and mortality. The recent approval of abiraterone and enzalutamide highlight the improvements which can be made targeting the androgen receptor (AR) axis. Nonetheless, resistance inevitably develops and there is c...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708177/ https://www.ncbi.nlm.nih.gov/pubmed/26816739 http://dx.doi.org/10.3978/j.issn.2223-4683.2013.09.09 |